EA033113B1 - Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта - Google Patents

Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта

Info

Publication number
EA033113B1
EA033113B1 EA201591269A EA201591269A EA033113B1 EA 033113 B1 EA033113 B1 EA 033113B1 EA 201591269 A EA201591269 A EA 201591269A EA 201591269 A EA201591269 A EA 201591269A EA 033113 B1 EA033113 B1 EA 033113B1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxide
roflumilast
inhalation
respiratory
methods
Prior art date
Application number
EA201591269A
Other languages
English (en)
Other versions
EA201591269A1 (ru
Inventor
Сваруп Кумар Ваккаланка
Original Assignee
Инкозен Терапьютикс Пвт. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инкозен Терапьютикс Пвт. Лтд. filed Critical Инкозен Терапьютикс Пвт. Лтд.
Publication of EA201591269A1 publication Critical patent/EA201591269A1/ru
Publication of EA033113B1 publication Critical patent/EA033113B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены применение ингаляционных фармацевтических композиций, содержащих N-оксид рофлумиласта, для лечения аутоиммунных, респираторных и/или воспалительных заболеваний и состояний и способ лечения указанных заболеваний и состояний, включающий ингаляционное введение N-оксида рофлумиласта или его фармацевтически приемлемой соли, характеризующихся dменее 6 мкм и вводимых в виде однократной дозы, составляющей от примерно 5 до примерно 2000 мкг.
EA201591269A 2013-01-28 2014-01-28 Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта EA033113B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN355CH2013 2013-01-28
IN354CH2013 2013-01-28
PCT/IB2014/058617 WO2014115127A1 (en) 2013-01-28 2014-01-28 Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide

Publications (2)

Publication Number Publication Date
EA201591269A1 EA201591269A1 (ru) 2016-01-29
EA033113B1 true EA033113B1 (ru) 2019-08-30

Family

ID=54196705

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591269A EA033113B1 (ru) 2013-01-28 2014-01-28 Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта

Country Status (25)

Country Link
US (3) US9649302B2 (ru)
EP (2) EP3763366A1 (ru)
JP (3) JP6426624B2 (ru)
KR (2) KR102154104B1 (ru)
CN (3) CN110464724A (ru)
AU (2) AU2014208359B2 (ru)
BR (1) BR112015017784A2 (ru)
CA (1) CA2897464C (ru)
CY (1) CY1123478T1 (ru)
DK (1) DK2948148T3 (ru)
EA (1) EA033113B1 (ru)
ES (1) ES2828070T3 (ru)
HK (1) HK1217427A1 (ru)
HR (1) HRP20201711T1 (ru)
HU (1) HUE052275T2 (ru)
IL (2) IL240154B (ru)
LT (1) LT2948148T (ru)
NZ (1) NZ710726A (ru)
PL (1) PL2948148T3 (ru)
PT (1) PT2948148T (ru)
RS (1) RS60985B1 (ru)
SG (2) SG11201505835QA (ru)
SI (1) SI2948148T1 (ru)
WO (1) WO2014115127A1 (ru)
ZA (1) ZA201505600B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN110464724A (zh) * 2013-01-28 2019-11-19 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
AU2018234059A1 (en) * 2017-03-16 2019-10-31 Takeda Gmbh Treatment of idiopathic pulmonary fibrosis
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
KR102507987B1 (ko) 2017-09-22 2023-03-21 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
GB201807286D0 (en) * 2018-05-03 2018-06-20 Dalsgaard Carl Johan New use
WO2020086759A2 (en) * 2018-10-23 2020-04-30 George Edward Hoag Composition and method for treating the lungs
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
TW202317080A (zh) * 2021-07-09 2023-05-01 美商阿斯特捷利康有限責任公司 用於氣溶膠遞送之組合物、方法及系統
GB2614901A (en) * 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations
CN117224482A (zh) * 2023-09-07 2023-12-15 苏州易合医药有限公司 一种用于治疗ipf疾病的吸入制剂及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001338A1 (de) * 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
WO2004047829A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag New synergistic combination comprising roflumilast and formoterol
WO2004084894A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US20060270667A1 (en) * 2005-05-31 2006-11-30 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100701904B1 (ko) * 1999-08-21 2007-04-02 알타나 파마 아게 Ｐｄｅ 억제제 및 베타 2 아드레날린수용체 작동제의상승적 조합
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP1289961A1 (en) 2000-05-25 2003-03-12 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
UA80393C2 (ru) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице
SI1658872T2 (sl) 2002-07-31 2019-12-31 Chiesi Farmacetuici S.P.A. Inhalator prahu
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
CA2550848C (en) * 2004-02-06 2013-02-26 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
US20070167496A1 (en) * 2004-02-27 2007-07-19 Attana Pharma Ag Roflumilast and glycopyrronium combination
WO2005107749A1 (en) 2004-05-10 2005-11-17 Altana Pharma Ag Use of roflumilast for the prophylaxis or treatment of emphysema
CN101163476A (zh) 2005-04-19 2008-04-16 尼科梅德有限责任公司 用于治疗肺动脉高血压的罗氟司特
GB0523653D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
PL2098248T3 (pl) * 2005-12-21 2012-11-30 Meda Pharma Gmbh & Co Kg Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych
KR20100023040A (ko) * 2007-06-21 2010-03-03 쉐링 코포레이션 폴리사이클릭 구아닌 유도체 및 이의 용도
DK2435024T3 (en) * 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
WO2011163469A1 (en) 2010-06-23 2011-12-29 Teva Pharmaceutical Industries Ltd. Hydrated form of anti-inflammatory roflumilast-n-oxide
RU2578975C2 (ru) * 2010-08-03 2016-03-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
CN110464724A (zh) * 2013-01-28 2019-11-19 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001338A1 (de) * 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
WO2004047829A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag New synergistic combination comprising roflumilast and formoterol
WO2004084894A1 (en) * 2003-03-28 2004-10-07 Altana Pharma Ag Synergistic combination comprising roflumilast and revatropate for the treatment of respiratory diseases
WO2006094942A1 (en) * 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
US20060270667A1 (en) * 2005-05-31 2006-11-30 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases

Also Published As

Publication number Publication date
SG10201911395UA (en) 2020-01-30
CY1123478T1 (el) 2022-03-24
HUE052275T2 (hu) 2021-04-28
KR20200105983A (ko) 2020-09-09
JP2020079295A (ja) 2020-05-28
KR20200006630A (ko) 2020-01-20
US20220008400A1 (en) 2022-01-13
JP6426624B2 (ja) 2018-11-21
BR112015017784A2 (pt) 2017-07-11
KR102154104B1 (ko) 2020-09-09
JP7015331B2 (ja) 2022-02-02
AU2018205077A1 (en) 2018-07-26
HRP20201711T1 (hr) 2020-12-25
IL240154B (en) 2020-03-31
CN104994854A (zh) 2015-10-21
PL2948148T3 (pl) 2021-01-25
EP3763366A1 (en) 2021-01-13
IL240154A0 (en) 2015-09-24
IL272701B1 (en) 2023-01-01
JP2016505067A (ja) 2016-02-18
SI2948148T1 (sl) 2020-12-31
US20140213560A1 (en) 2014-07-31
ZA201505600B (en) 2016-12-21
AU2018205077B2 (en) 2020-02-20
DK2948148T3 (da) 2020-10-26
IL272701B2 (en) 2023-05-01
PT2948148T (pt) 2020-11-03
HK1217427A1 (zh) 2017-01-13
SG11201505835QA (en) 2015-08-28
AU2014208359B2 (en) 2018-04-26
CN110403922A (zh) 2019-11-05
US11103488B2 (en) 2021-08-31
CA2897464A1 (en) 2014-07-31
EP2948148A1 (en) 2015-12-02
CA2897464C (en) 2021-05-18
US9649302B2 (en) 2017-05-16
EP2948148B1 (en) 2020-07-29
WO2014115127A1 (en) 2014-07-31
IL272701A (en) 2020-04-30
EA201591269A1 (ru) 2016-01-29
RS60985B1 (sr) 2020-11-30
US20170196843A1 (en) 2017-07-13
AU2014208359A1 (en) 2015-08-20
JP2018168172A (ja) 2018-11-01
CN110464724A (zh) 2019-11-19
NZ710726A (en) 2020-08-28
LT2948148T (lt) 2020-12-28
ES2828070T3 (es) 2021-05-25

Similar Documents

Publication Publication Date Title
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MY176176A (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
PH12016501735A1 (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MD4539B1 (ru) Замещенные 4-фенилпиридины для лечения заболеваний связанных с рецептором NK-1
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2015012435A (es) Derivados de 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
PH12015501531A1 (en) Crenolanib for treating flt3 mutated proliferative disorders
MX2018006247A (es) Metodos para tratar la enfermedad de alzheimer y trastornos relacionados.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
EA201990606A1 (ru) Распыляемый тиотропий
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
MX2014003867A (es) Tratamiento de rinitis.